Candida: Some Thoughts

Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 2000)

Abstract

Candida infection as a local problem is well recognized in the normal population but even more commonly encountered in populations with impaired immune responses and increased susceptibility to Candida colonization. There is a gradation of colonization from that which is asymptomatic, through symptomatic, and at the far end of the spectrum the septicemic version of the disease. Paradoxically the complexity of diagnosis increases with the severity of the disease such that Candida septicemia is difficult to diagnose.

Keywords

Fatigue Toxicity Catheter Oncol Warfarin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexander JW, Boyce ST, Babcock GF, et al (1990) The process of microbial translocation. Ann Surg 212: 496–510PubMedCrossRefGoogle Scholar
  2. 2.
    Berg R, Bernasconi P, Fowler D, Gautreaux M (1993) Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis 168: 1314–1318PubMedCrossRefGoogle Scholar
  3. 3.
    Damjanovic V, Connolly CM, van Saene HK, et al (1993) Selective decontamination with nystatin for control of a Candida outbreak in a neonatal intensive care unit. J Hosp Infect 24: 245–259PubMedCrossRefGoogle Scholar
  4. 4.
    Inoue S, Peck MD, Alexander JW (1991) Fungal translocation is associated with increased mortality after thermal injury in guinea pigs. J Burn Care Rehabil 12: 19–22PubMedCrossRefGoogle Scholar
  5. 5.
    Wells CL (1990) Relationship between intestinal microecology and the translocation of intestinal bacteria. Antonie Van Leeuwenhoek 58: 87–93PubMedCrossRefGoogle Scholar
  6. 6.
    Jarvis WR, Martone WJ (1992) Predominant pathogens in hospital infections. J Antimicrob Chemother 29: 19–24PubMedCrossRefGoogle Scholar
  7. 7.
    Jarvis WR (1995) Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 20: 1526–1530PubMedCrossRefGoogle Scholar
  8. 8.
    Harvey RL, Myers JP (1987) Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 147: 2117–2120PubMedCrossRefGoogle Scholar
  9. 9.
    Anaissie E, Bodey GP (1989) Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 3: 867–882Google Scholar
  10. 10.
    Beck Sague C, Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. National Nosocomial Infections Surveillance System. J Infect Dis 167: 1247–1251Google Scholar
  11. 11.
    Morrison AJ Jr, Freer CV, Searcy MA, Landry SM, Wenzel RP (1986) Nosocomial bloodstream infections: secular trends in a statewide surveillance program in Virginia. Infect Control 7: 550–553PubMedGoogle Scholar
  12. 12.
    Pfaller M, Wenzel R (1992) Impact of the changing epidemiology of fungal infections in the (1990s. Eur J Clin Microbiol Infect Dis 11: 287–291PubMedCrossRefGoogle Scholar
  13. 13.
    Safran DB, Dawson E (1997) The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit. Arch Surg 132: 1184–1189PubMedCrossRefGoogle Scholar
  14. 14.
    Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325: 1274–1277PubMedCrossRefGoogle Scholar
  15. 15.
    Abi Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24: 1122–1128CrossRefGoogle Scholar
  16. 16.
    Plouffe JF, Brown DG, Silva J Jr, Eck T, Stricof RL, Fekety FR Jr (1977) Nosocomial outbreak of Candida parapsilosis fungemia related to intravenous infusions. Arch Intern Med 137: 1686–1689PubMedCrossRefGoogle Scholar
  17. 17.
    Huang YC, Lin TY, Peng HL, Wu JH, Chang HY, Leu HS (1998) Outbreak of Candida albicans fungaemia in a neonatal intensive care unit. Scand J Infect Dis 30: 137–142PubMedCrossRefGoogle Scholar
  18. 18.
    Huang YC, Lin TY, Leu HS, Peng HL, Wu JH, Chang HY (1999) Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 27: 97–102PubMedCrossRefGoogle Scholar
  19. 19.
    Pfaller MA (1994) Epidemiology and control of fungal infections. Clin Infect Dis 19 (suppl 1): S8 - S13PubMedCrossRefGoogle Scholar
  20. 20.
    Solomkin JS, Flohr AM, Simmons RL (1982) Indications for therapy for fungemia in postoperative patients. Arch Surg 117: 1272–1275PubMedCrossRefGoogle Scholar
  21. 21.
    Krcmery V Jr, Spanik S, Grausova S, et al (1998) Candida parapsilosis fungemia in cancer patients–incidence, risk factors and outcome. Neoplasma 45: 336–342Google Scholar
  22. 22.
    Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al (1997) Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 23: 23–30Google Scholar
  23. 23.
    Pittet D, Tarara D, Wenzel RP (1994) Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271: 1598–1601Google Scholar
  24. 24.
    Pittet D, Wenzel RP (1995) Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 155: 1177–1184Google Scholar
  25. 25.
    Wenzel RP (1995) Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20: 1531–1534PubMedCrossRefGoogle Scholar
  26. 26.
    Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148: 2642–2645Google Scholar
  27. 27.
    Palmer DL (1984) Microbiology of pneumonia in the patient at risk. Am J Med 76: 53–60PubMedCrossRefGoogle Scholar
  28. 28.
    el Ebiary M, Torres A, Fabregas N, et al (1997) Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 156: 583–590Google Scholar
  29. 29.
    Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220: 751–758Google Scholar
  30. 30.
    Barzotta A, Beardsley K (1999) Candida infection in critically ill trauma patients) a retrospective case-control study. Arch Surg 134: 657–664Google Scholar
  31. 31.
    Solomkin J, Flohr A, Quie P, Simmons R (1980) The role of Candida in intraperitoneal infections. Surgery 88: 524–530PubMedGoogle Scholar
  32. 32.
    British S, for Antimicrobial Chemotherapy Working Party (1994) Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 20: 522–528Google Scholar
  33. 33.
    Nolla Salas J, Leon C, Torres Rodriguez JM, Martin E, Sitges Serra A (1992) Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 14: 952–954CrossRefGoogle Scholar
  34. 34.
    Odds FC, Vranckx L, Woestenborghs F (1995) Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 39: 2051–2060PubMedCrossRefGoogle Scholar
  35. 35.
    Morace G, Sanguinetti M, Posteraro B, Pagano L (1995) In vitro susceptibility of Candida species isolated from patients with haematological malignancies. Mycoses 38: 59–67PubMedCrossRefGoogle Scholar
  36. 36.
    Rodero LL, Davel GO, Vivot W, Canteros CE, Fernandez C (1995) In vitro sensitivity tests for yeasts: evaluation of a micromethod. Rev Argent Microbiol 27: 81–89PubMedGoogle Scholar
  37. 37.
    Schmalreck AF, Kottmann I, Reiser A, Ruffer U, Scharr E, Vanca E (1995) An evaluation of seven methods of testing in vitro susceptibility of clinical yeast isolates to fluconazole. Mycoses 38: 359–368PubMedCrossRefGoogle Scholar
  38. 38.
    Wanger A, Mills K, Nelson PW, Rex JH (1995) Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 39: 2520–2522PubMedCrossRefGoogle Scholar
  39. 39.
    Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE (1996) Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 173: 219–225PubMedCrossRefGoogle Scholar
  40. 40.
    Manso E, Montillo M, Discepoli G, Leoni P (1991) Fluconazole resistance of Candida krusei. Boll Ist Sieroter Milan 70: 527–529PubMedGoogle Scholar
  41. 41.
    Marr KA, White TC, van Burik JA, Bowden RA (1997) Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 25: 908–910PubMedCrossRefGoogle Scholar
  42. 42.
    Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J (1995) Mechanisms of resistance to azote antifungal agents in Candida albicans isolates from AIDS patients involve specific multi-drug transporters. Antimicrob Agents Chemother 39: 2378–2386PubMedCrossRefGoogle Scholar
  43. 43.
    Tumbarello M, Tacconelli E, Caldarola G, Morace G, Cauda R, Ortona L (1997) Fluconazole resistant oral candidiasis in HIV-infected patients. Oral Dis 3: S110 - S112PubMedGoogle Scholar
  44. 44.
    Smith LG (1986) Fungal nosocomial superinfection. N Engl J Med 83: 597–598Google Scholar
  45. 45.
    Cerra F, Maddaus M, Dunn D, et al (1992) Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. Arch Surg 127: 163–169PubMedCrossRefGoogle Scholar
  46. 46.
    Desai M, Rutan R, Heggers J, Herndon D (1992) Candida infection with and without nystatin prophylaxis. Arch Surg 127: 159–162Google Scholar
  47. 47.
    Savino J, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L (1994) Routine prophylactic anti-fungal agents (clotrimazole, ketoconazole, and nystatin) in non transplant, non burned, critically ill surgical and trauma patients. J Trauma 36: 20–26PubMedCrossRefGoogle Scholar
  48. 48.
    Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK (1996) A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 28: 549–552PubMedCrossRefGoogle Scholar
  49. 49.
    Lumbreras C, Cuervas Mons V, Jara P, et al (1996) Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 174: 583–588PubMedCrossRefGoogle Scholar
  50. 50.
    Ninane J (1994) A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 13: 330–337PubMedCrossRefGoogle Scholar
  51. 51.
    Milliken ST, Powles RL (1990) Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 12: 5374–5379CrossRefGoogle Scholar
  52. 52.
    Alvarez Alvarez ME, Sanchez Sousa A, Baquero F (1998) A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis. Rev Esp Quimioter 11: 295–315Google Scholar
  53. 53.
    Janknegt R, de Marie S, Bakker-Woudenberg I, Crommelin D (1992) Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 23: 279–291PubMedCrossRefGoogle Scholar
  54. 54.
    Anaissie EJ, Vartivarian SE, Abi Said D, et al (1996) Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101: 170–176PubMedCrossRefGoogle Scholar
  55. 55.
    Abele Horn M, Kopp A, Sternberg U, et al (1996) A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 24: 426–432CrossRefGoogle Scholar
  56. 56.
    Martino P, Girmenia C (1997) Are we making progress in antifungal therapy? Curr Opin Oncol 9: 314–320PubMedCrossRefGoogle Scholar
  57. 57.
    Adler-Moore J, Proffitt R (1993) Development characterization efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposomal Res 3: 429–450CrossRefGoogle Scholar
  58. 58.
    Mehta RT, Poddar S, Kalidas M, Gomez Flores R, Dulski K (1997) Role of macrophages in the candidacidal activity of liposomal amphotericin B. J Infect Dis 175: 214–217PubMedCrossRefGoogle Scholar
  59. 59.
    Ralph ED, Barber KR, Grant CW (1991) Liposomal amphotericin B: an effective, nontoxic preparation for the treatment of urinary tract infections caused by Candida albicans. Am J Nephrol 11: 118–122PubMedCrossRefGoogle Scholar
  60. 60.
    Ralph ED, Khazindar AM, Barber KR, Grant CW (1991) Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother 35: 188–191PubMedCrossRefGoogle Scholar
  61. 61.
    Lister J (1996) Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 56 (suppl 57): 18–23CrossRefGoogle Scholar
  62. 62.
    White MH, Bowden RA, Sandler ES, et al (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27: 296–302PubMedCrossRefGoogle Scholar
  63. 63.
    Herbrecht R (1997) Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 16: 74–80PubMedCrossRefGoogle Scholar
  64. 64.
    de Marie S (1996) Liposomal and lipid-based formulations of amphotericin B. Leukemia 10: S93 - S96Google Scholar
  65. 65.
    Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ (1998) Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 26: 461–467PubMedCrossRefGoogle Scholar
  66. 66.
    Anaissie EJ, Mattiuzzi GN, Miller CB, et al (1998) Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 42: 606–611PubMedGoogle Scholar
  67. 67.
    Oppenheim BA, Herbrecht R, Kusne S (1995) The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 21: 1145–1153PubMedCrossRefGoogle Scholar
  68. 68.
    Nicolau DP, Crowe H, Nightingale CH, Quintiliani R (1995) Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 36: 395–401PubMedCrossRefGoogle Scholar
  69. 69.
    Desai MH, Rutan RL, Heggers JP, Herndon DN (1992) Candida infection with and without nystatin prophylaxis. A 11-year experience with patients with burn injury. Arch Surg 127: 159–162Google Scholar
  70. 70.
    Gupta TP, Ehrinpreis MN (1990) Candida-associated diarrhea in hospitalized patients. Gastroenterology 98: 780–785PubMedGoogle Scholar
  71. 71.
    Dube MP, Heseltine PN, Rinaldi MG, Evans S, Zawacki B (1994) Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin Infect Dis 18: 77–82PubMedCrossRefGoogle Scholar
  72. 72.
    Sheridan RL, Weber JM, Budkevich LG, Tompkins RG (1995) Candidemia in the pediatric patient with burns. J Burn Care Rehabil 16: 440–443PubMedCrossRefGoogle Scholar
  73. 73.
    Slotman G, Burchard K (1987) Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 122: 147–151PubMedCrossRefGoogle Scholar
  74. 74.
    Girmenia C, Martino P, Cassone A (1996) Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies. Blood 87: 838–839PubMedGoogle Scholar
  75. 75.
    Le Guennec R, Reynes J, Mallie M, Pujol C, Janbon F, Bastide JM (1995) Fluconazole-and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol 33: 2732–2737PubMedGoogle Scholar
  76. 76.
    Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R (1993) Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 37: 1847–1849PubMedCrossRefGoogle Scholar
  77. 77.
    Epstein JB, Ransier A, Lunn R, et al (1996) Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81: 291–296PubMedCrossRefGoogle Scholar
  78. 78.
    Eggiman P, Francioli P, Schneider R, et al (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high risk surgical patients. Crit Care Med 27: 1066–1072CrossRefGoogle Scholar
  79. 79.
    Rex 1 (1996) Catheters and candidemia. Clin Infect Dis 22: 467–469PubMedCrossRefGoogle Scholar
  80. 80.
    Rex J, Bennett J, Sugar A, et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331: 1325–1330PubMedCrossRefGoogle Scholar
  81. 81.
    Nguyen MH, Peacock JE Jr, Tanner DC, et al (1995) Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 155: 2429–2435Google Scholar
  82. 82.
    Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A (1993) Treatment of Candida albicans fungaemia with fluconazole. J Infect 26: 133–146PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • N. Soni

There are no affiliations available

Personalised recommendations